A retrospective case-control study was conducted to determine why some infants born full-term without obstetric intervention to hepatitis B e antigen (HBeAg) the high-risk characteristics identified in the case-control study, we provide a descriptive account of a molecular epidemiologiPrompt postnatal vaccination of at-risk infants effectively curtails perinatal infection, particularly when added protection is cal investigation into a transmission chain traced to a child who became infected after birth despite having received full provided by hepatitis B immunoglobulin (HBIg) given shortly after birth. Nevertheless, a small proportion of those receiving passive-active immunoprophylaxis. complete passive-active prophylaxis become infected [4 -6]. In these infected infants, the risks of developing sequelae of chronic infection [7] and transmitting HBV remain.
Hepatitis B virus (HBV) infection remains globally endemic.
have associated such ''breakthrough'' infections with intrauterine infection [6] , high-level maternal viremia [12 -14] , and Transmission from mother to infant plays an important role in maintenance of endemicity, especially in regions where such infection by vaccine-escape HBV mutants [15] . We report a case-control study of neonatal breakthrough infection is hyperendemic, e.g., East Asia [1] . Since a large fraction of vertical infections progress to chronicity [2] , in-HBV infection, showing that nucleotide changes at certain alleles in the genome of maternal HBV and high-level maternal fected infants can in their lifetime be capable of initiating new cycles of both horizontal and vertical infection.
viremia may be risk factors. In addition, to illustrate the public health impact of perinatal infection by an HBV variant with Infants born to hepatitis B e antigen (HBeAg) -positive mothers are at risk of acquiring infection maternally [3] .
the high-risk characteristics identified in the case-control study, we provide a descriptive account of a molecular epidemiologiPrompt postnatal vaccination of at-risk infants effectively curtails perinatal infection, particularly when added protection is cal investigation into a transmission chain traced to a child who became infected after birth despite having received full provided by hepatitis B immunoglobulin (HBIg) given shortly after birth. Nevertheless, a small proportion of those receiving passive-active immunoprophylaxis. complete passive-active prophylaxis become infected [4 -6] . In these infected infants, the risks of developing sequelae of chronic infection [7] and transmitting HBV remain.
Patients and Methods

In the course of monitoring the outcome for at-risk infants in
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England and Wales, we observed some postvaccination failures among neonates born to HBeAg-positive mothers. In certain
The Public Health Laboratory Service administers a surveilinstances, failure could be attributed to factors that predispose lance scheme in England and Wales for infants at risk of acquirto perinatal infection, such as prematurity [8] , prolonged labor ing HBV infection. In this scheme, a database is kept of the [9], delay or omission of HBIg administration, and failure to age, ethnicity, parity, and HBeAg status of hepatitis B surface achieve full vaccination [10, 11] . However, HBV infection was antigen (HBsAg) -positive mothers, and in relation to their also noted in full-term infants who were delivered without infants, the obstetric history, vaccination schedule, dosage and obstetric intervention and given full prophylaxis. Past studies batch numbers of HBIg and vaccine, and HBV serological status at age 1 year [16] . Data were extracted from records of infants born between 1 June 1988 and 30 May 1995 to assess the prevalence of HBV infection in neonates who were deliv-nally without assistance at or after 36 weeks' gestation; (2) they er's age, gravidity, and ethnicity; and maternal HBV titer, genotype, and base changes at non-genotype-specifying positions received 200 IU of HBIg (Bio Products Laboratory, Elstree, England) within 48 hours after birth; (3) they received three in the surface gene amplicons. The maternal HBV DNA titer was analyzed both as a continuous variable (expressed as gedoses of hepatitis B vaccine (Engerix B; SmithKline Beecham, Welwyn Garden City, England) (0.5 mL each, containing 10 nome copies/mL) and as a dichotomous variable (the number of mothers who carry 10 8 or §10 8 genome copies per mL of mg of HBsAg) at 0, 1, and 6 months of age; and (4) they underwent postvaccination serological testing for HBsAg.
HBV DNA). The value of 10 8 genome copies/mL was chosen because it divided the number of mothers into two roughly equal sets. Lot differences in HBIg and Engerix B were examVirological Studies ined as potential variables, but the diversity in batch numbers Specimens. To assess virological parameters that might acof the two products was too wide for inclusion in the analysis. count for the difference in outcomes of the infants' infections Data were analyzed with use of statistical packages. Exact following immunoprophylaxis, antenatal booking sera (usually logistic regression was also used in multivariable analyses to obtained at the end of the first trimester) from mothers of investigate the joint effects of various pairs of variables. It was infants found to be HBsAg-positive at postvaccination testing not possible to include ú2 variables in any given model, owing were examined. Available antenatal sera from HBeAg-positive to the small sample size and the high degree of correlation mothers of infants who were HBsAg-negative at postvaccinabetween many of the genetic variables (particularly allelic base tion testing were used as controls. Sera from infected infants substitutions that specify genotype). Logistic regression also were additionally studied to compare the nucleotide sequences enabled calculation of odds ratios adjusted for the effects of of HBV circulating in them and in their mothers. In the separate maternal HBV DNA titer and variation in the genotype or study of HBV transmission linked to an HBsAg-positive child, allele. we studied sera obtained from contacts who developed acute Analyses were based on the assumption that each mother-HBV infection as well as sera and saliva from the child.
infant transmission was an independent event. Hence, variables HBV strain differentiation. DNA in specimens was exfor mothers with sequential pregnancies were considered sepatracted by a silica/guanidium thiocyanate -based method [17] .
rately. No multiple pregnancies were encountered. Saliva was first subjected to ultracentrifugation before extraction. From each extract, a 476-bp segment from the surface Descriptive Account of HBV Transmissions Linked to a antigen -coding region (hereafter the ''surface gene'') between Child with Breakthrough Infection nucleotide positions 82 and 558 was amplified by nested PCR. This segment was chosen because it encompasses sites in the A male infant, X, was born at 40 weeks' gestation in 1990 surface gene that are regarded to confer antigenicity to HBsAg to a 22-year-old white woman, M, who had been discovered [18 -20] . PCR primer sequences and cycling conditions used at antenatal evaluation to have detectable HBsAg and HBeAg. in this study have been specified elsewhere [21] .
X was delivered vaginally and was given HBIg and the first Strain differences in the surface gene were scanned by using dose of hepatitis B vaccine at different gluteal sites 1 hour after a single-strand conformation polymorphism (SSCP) analytic birth. The postnatal course was uneventful, and he received the procedure on the amplified products, performed essentially as second and third doses of the vaccine at 1 and 6 months of described previously [21] . DNA in the amplified products was age. During postvaccination testing at age 1 year, his blood sequenced with use of the Taq DyeDeoxy Terminator Cycle was found to be positive for HBsAg and HBeAg. Sequencing Kit and the ABI 373A DNA Sequencer (both from
In 1992, a 52-year-old woman, A, who was providing dayPerkin Elmer, Forest City, CA). HBV genotypic assignments care for X developed acute hepatitis B; she had no risk factors were based on genotype-specific nucleotide motifs in the surfor HBV infection except contact with X. In 1994, a 6-yearface genes [22] . For viral load estimation and for the observaold boy, B, who was a playmate of X in a nursery school tional study, a 263-bp segment from the core antigen -coding facility, developed acute hepatitis B. In 1995, a 3-year-old girl, region (hereafter the ''core gene''), from positions 1,891 -C, who attended the same nursery school, developed jaundice. 2,154, was also amplified.
Serological investigations confirmed acute hepatitis B. Her Viral load estimation. Following a series of 10-fold dilufamily members were screened and found to be seronegative tions of each serum, DNA was extracted from each dilution for HBsAg. and processed for PCR amplification of the core gene fragment.
Saliva specimens obtained from the rest of X's nursery The end-point was compared to that of a similar dilution series school contacts and sera drawn from the nursery school supermade from 1 ng of the plasmid pHBV130.
visors tested negative for antibody to the hepatitis B core antigen [23] . A, B, and C all cleared HBsAg within 6 months of
Statistical Analyses
infection. M remained an HBeAg-positive carrier and subsequently gave birth to two other children. They were delivered Variables examined were as follows: infant's birth weight; time between delivery and the administration of HBIg; mothvaginally at full term, received passive-active immunoprophy-/ 9c51$$jy11 06-15-98 22:56:56 cida UC: CID laxis, and were HBsAg-negative when tested at age 1 year. between the two groups in the distribution of maternal HBV genotypes was of interest only when type C was compared Both were included as controls in the case-control study. X is one of the cases in the case-control study.
with other types. Table 2 shows that infants whose mothers were infected by non-C (A, B, D, and E) genotypes were at HBV DNA sequences matching those of the corresponding mothers were included as cases in this study. lating HBV, and number of mothers with an HBV titer (genome † Cases: genotypes B (n Å 3), D (n Å 6), and E (n Å 1). Controls: genotypes A (n Å 1), B (n Å 2), and D (n Å 8).
Results
Case-Control Study
copies) §10 8 /mL were not significant ( higher risk of infection than those whose mothers carried genotime of pregnancy, serum from X at age 1 year, and serum from the three contacts (A, B, and C) during acute hepatitis, type C, although this did not reach the 5% significance level.
Comparison of DNA sequences in the surface gene amplias well as saliva from X collected during the investigation into C's hepatitis. Note that the study specimens had been collected cons derived from mothers of cases and controls did not reveal base changes that were unique to mothers of the cases. Base over 6 years. Figure 1 also shows that sera from two unrelated cases of acute hepatitis B and the control plasmid yielded substitutions at allelic sites were then examined. Substitutions at the following nonneutral allelic positions were compared: different banding patterns. DNA sequencing confirmed the sequence identity of HBV in all the serum samples and in the  136, 139, 146, 158, 167, 170, 176, 191, 203, 254, 328 ) were significantly associated with infection independently of titer.
background of the study subjects, total number of HBIg injections given (ranging from 1 to 7), HBIg dosage (as fixed doses or calculated according to body weight), anti-HBsAg content
Molecular Epidemiology of HBV Transmission Linked to
of HBIg (varying according to the antibody levels prevailing
Breakthrough Infection
in plasma donors), and vaccine type (plasma-or yeast-derived), Identical banding patterns (figure 1) were produced in the dose (ranging from 2 mg to 30 mg of HBsAg), and schedule SSCP assay procedure by amplicons derived from the surface (3-or 4-dose, with varying intervals between each dose). and core genes of HBV in serum from X's mother (M) at the Few studies have considered, in addition, variation due to obstetric factors. We excluded this consideration by restricting the study to infants who were delivered full-term and without infants born without obstetric intervention to HBeAg-positive mothers during the study period served as the denominator for estimating the HBsAg carriage rate. In the United Kingdom, the failure to vaccinate at-risk infants against HBV completely and to fully achieve postvaccination testing is a recognized problem [10] . Another limitation arises from the restricted availability of mother-infant serum pairs for use as controls. Several reporting laboratories were not able to provide archived HBsAg-positive sera for our study. The small size of the control group, as well as that of the case group, accounts for the relatively wide confidence intervals observed in the odds ratios. The DNA sequence of the maternal viral genome was not examined in its entirety. Consequently, the possibility that residues other than the four identified here, particularly in non-C genotypes, are associated with increased risk could not be excluded. However, that the four changes in the surface gene are all missense mutations may be significant. In early studies, investigators using synthetic peptides located the immunodominant a antigen, against which neutralizing antibodies are raised, as residing between codons 138 to 149 of HBsAg [19, 20] . Later studies, with use of mutagenesis [29] and amino acid replacement assays of immunizing oligopeptides [30] , identified key antigenic residues at a disulphide loop stretching from codons 140 to 146. discontinuous epitopes between codons 101 and 207 [33] . Hence three of the four missense mutations (at positions 328, 377, and 479) lie within regions that specify HBsAg epitopes. an independent increase in risk. In this respect, the finding agrees with data from previous studies [12 -14] . The indepenThe extent to which the newly characterized epitopes contribute to the antigenicity of the a determinant is not clear; they may dent effect of viremia is further exemplified in the case of the mother (M) of the source (X) of the HBV transmission series play accessory roles in eliciting antibodies with specificities and affinities different from those elicited by the more immunodomistudied in detail in this report: while the sequence of HBV carried by M remained identical throughout the three pregnannant epitopes of the a determinant. The base changes in codon 122 are particularly significant. In this codon, G 365 specifies argicies, it was only during her pregnancy with X, when the level of viremia was high, that breakthrough infection occurred.
nine while A 365 specifies lysine, and these are the key determinants of the y and d subtype, respectively [22] . However, our study identifies allelic substitutions at positions 158, 328, 365, 377, 479, and 2,064 as additional risk
It is interesting to note that Lelie et al.
[34] observed subtype y occurring more commonly than d in their series of infants factors. Thus, when viremia was included as a predictor in multivariable analysis, the base changes at positions 158, 328, with breakthrough infection. It is possible that the mutation affecting this codon, and perhaps those involving codons 110 365, and 479 were seen to increase in significance and gave higher estimated odds ratios. Owing to the small size of this and 160, interferes with the suppression of perinatally transmitted HBV by HBIg [35, 36] and by vaccine-induced antibody study and the many variables examined, it was not possible to show which of the identified risk factors would be the best [37] . The chances of failure to clear the virus may be enhanced when the exposure dose is high. The findings in our study of serial HBV transmission exem- The problem of preventing chronic HBV infection in the
